{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:18:54Z","timestamp":1780359534040,"version":"3.54.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.blre.2023.101142","type":"journal-article","created":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T19:01:05Z","timestamp":1699729265000},"page":"101142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["A personalized, organ-based approach to the treatment of chronic steroid-refractory graft-versus-host disease"],"prefix":"10.1016","volume":"63","author":[{"given":"Hanaa","family":"Fatoum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Zeiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrukh K.","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2023.101142_bb0005","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease - biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101142_bb0010","first-page":"31","article-title":"Graft-versus-host disease: a complex long-term side effect of hematopoietic stem cell transplant","volume":"22","author":"Barton-Burke","year":"2008","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.blre.2023.101142_bb0015","article-title":"Long-term care after hematopoietic-cell transplantation in adults","volume":"347","author":"Boeckh","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101142_bb0020","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1750-1172-2-35","article-title":"Acute graft versus host disease","volume":"2","author":"Jacobsohn","year":"2007","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.blre.2023.101142_bb0025","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1002\/cncr.20613","article-title":"Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management","volume":"101","author":"Couriel","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2023.101142_bb0030","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF02983793","article-title":"The pathophysiology of acute graft-versus-host disease","volume":"78","author":"Ferrara","year":"2003","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2023.101142_bb0035","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/bbmt.2003.50026","article-title":"Chronic graft-versus-host disease","volume":"9","author":"Lee","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101142_bb0040","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.bbmt.2006.01.008","article-title":"Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. Response criteria working group report","volume":"12","author":"Pavletic","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101142_bb0045","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/sj.bmt.1705434","article-title":"Quality of life associated with acute and chronic graft-versus-host disease","volume":"38","author":"Lee","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101142_bb0050","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-11-319509","article-title":"Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the chronic GVHD consortium","volume":"117","author":"Pidala","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101142_bb0055","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/sj.bmt.1703677","article-title":"Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation","volume":"30","author":"Worel","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101142_bb0060","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12955-020-01651-2","article-title":"\u201cIs this the GVHD?\u201d a qualitative exploration of quality of life issues in individuals with graft-versus-host disease following allogeneic stem cell transplant and their experiences of a specialist multidisciplinary bone marrow transplant service","volume":"19","author":"De Vere","year":"2021","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.blre.2023.101142_bb0065","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood-2014-08-551994","article-title":"How we treat chronic graft-versus-host disease","volume":"125","author":"Flowers","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101142_bb0070","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.bbmt.2008.09.017","article-title":"Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease","volume":"14","author":"Flowers","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101142_bb0075","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2014-03-563544","article-title":"Failure-free survival after initial systemic treatment of chronic graft-versus-host disease","volume":"124","author":"Inamoto","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101142_bb0080","unstructured":"NCCN Guidelines for patients: Graft versus host disease 2021 n.d."},{"key":"10.1016\/j.blre.2023.101142_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101142_bb0090","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.22.00958","article-title":"Axatilimab for chronic graft-versus-host disease after failure of at least two prior systemic therapies: results of a phase I\/II study","volume":"41","author":"Kitko","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101142_bb0095","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1172\/JCI75935","article-title":"CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease","volume":"124","author":"Alexander","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2023.101142_bb0100","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3324\/haematol.2010.026104","article-title":"Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study","volume":"95","author":"Kim","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2023.101142_bb0105","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood.2021012021","article-title":"Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar study","volume":"138","author":"Cutler","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101142_bb0110","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101142_bb0115","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1182\/blood-2013-05-494278","article-title":"Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD","volume":"122","author":"Olivieri","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101142_bb0120","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/bmt.2015.298","article-title":"Phase-1\/\u22122 study of pomalidomide in chronic GvHD","volume":"51","author":"Pusic","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101142_bb0125","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101142_bb0130","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2017-05-780239","article-title":"Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease","volume":"131","author":"Nahas","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101142_bb0135","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and regulatory T cells in graft-versus-host disease","volume":"365","author":"Koreth","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101142_bb0140","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2008-03-141481","article-title":"A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease","volume":"112","author":"Flowers","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101142_bb0145","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/bmt.2010.195","article-title":"Mesenchymal stem cell as salvage treatment for refractory chronic GVHD","volume":"45","author":"Weng","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101142_bb0150","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.bbmt.2013.02.009","article-title":"Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease","volume":"19","author":"Nikiforow","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101142_bb0155","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.bbmt.2019.09.002","article-title":"Carfilzomib for treatment of refractory chronic graft-versus-host disease: a chronic GVHD consortium pilot phase II trial","volume":"26","author":"Pidala","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2023.101142_bb0160","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1182\/blood-2018-04-785899","article-title":"How I treat refractory chronic graft-versus-host disease","volume":"133","author":"Sarantopoulos","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101142_bb0165","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1365-2141.2012.09128.x","article-title":"Diagnosis and management of chronic graft-versus-host disease","volume":"158","author":"Dignan","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101142_bb0170","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/j.bbmt.2018.03.008","article-title":"Steroid refractory chronic graft-versus-host disease: cost-effectiveness analysis","volume":"24","author":"Yalniz","year":"2018","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23001030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23001030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:30:50Z","timestamp":1759437050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X23001030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":34,"alternative-id":["S0268960X23001030"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2023.101142","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A personalized, organ-based approach to the treatment of chronic steroid-refractory graft-versus-host disease","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2023.101142","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101142"}}